Request An Appointment


Lung Cancer

The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or  via email

A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN

A Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects with Active Non-Hematological Cancers

A Randomized Phase 2 Trial of AM0010 in Combination with Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects with Stage IV/Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1

A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression

Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer

A Study to determine the concordance of key actionable genomic alterations as assessed in tumor tissue and plasma from patients with non small cell lung carcinoma (NSCLC)

A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3 high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy

Phase 1b/2a Safety and Pharmacokinetic Study of GIT28 in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study pf Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)

A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors

Evaluation of the TR(ACE)(R) Assay for the Ability to Aid in Monitoring Disease Progress, Response to Therapy or for the Recurrent or Residual Disease for Patients with Previously Diagnosed Cancers (Stage III and IV Lung and Stage IV Breast)

A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients with Advanced/Recurrent Non-Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin AVANA

A Tissue Acquisition Study for the Development of a Methodology to Select Tumor-Specific Neo-Antigens for the Treatment of NSCLC

A randomized parallel group phase III trial of OSE 2101 as 2nd line after prior platinum-based chemotherapy failure or as 3rd line after platinum-failure and checkpoint inhibitor-failure, compared with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) unsuitable for radiotherapy or metastatic Non-Small-Cell Lung Cancer. (OSE2101C301)

A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer

An Open-Label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refactory Solid Tumors or Hematological Malignancies Who Have Mild, Moderate, and Severe Renal Impairment

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

An Open-Label Study to Assess the Safety and Tolerability of Active Immunotherapy with Escalating Doses of OBI-833/OBI-821 (Globo H- CRM197/Adjuvant) in Subjects with Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer

Return to Clinical Trials at GCC